We derived two TRAIL-resistant HL-60 subclones, HL-60/P1 and HL-60/P2, from a TRAIL-sensitive HL-60 acute promyelocytic leukemia cell line and performed expression proteomics analysis. We identified potential molecular targets for selective elimination of resistant cells and proposed and successfuly tested several treatments leading to selective elimination of TRAIL-resistant cells.